This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Here's Why Ocugen (OCGN) Stock Has More Than Tripled This Year
by Zacks Equity Research
Ocugen's (OCGN) stock rides on the company's collaboration with India's Bharat Biotech to co-develop and commercialize the latter's COVID-19 vaccine, COVAXIN, for the U.S. market.
RGENNegative Net Change AVIRPositive Net Change BNTXNegative Net Change OCGNPositive Net Change
biotechs
Biotech Stock Roundup: AGEN, SRPT Surge & BIIB, REGN Provide Pipeline Updates
by Zacks Equity Research
The biotech sector was in focus last week with pipeline and regulatory updates from Agenus (AGEN) and Sarepta (SRPT), among others.
BIIBNegative Net Change REGNNegative Net Change RHHBYNegative Net Change BMYNegative Net Change AGENPositive Net Change SRPTPositive Net Change
biotechs pharmaceuticals
BioNTech (BNTX) Up More Than 100% So Far This Year: Here's Why
by Zacks Equity Research
BioNTech (BNTX) is riding high on the robust performance of its COVID-19 vaccine, BNT162b2, which has been developed in partnership with Pfizer.
AZNNegative Net Change MRNANegative Net Change BNTXNegative Net Change
biotechs
Bristol-Myers (BMY) Teams Up With Agenus for Antibody Program
by Zacks Equity Research
Bristol-Myers (BMY) obtains exclusive license for Agenus' antibody program, AGEN1777, for an upfront payment of $200 million and up to $1.36 billion in milestone payments.
BMYNegative Net Change AGENPositive Net Change RGENNegative Net Change
biotechs
Here's Why Entera Bio (ENTX) Stock Has Almost Tripled This Year
by Zacks Equity Research
Entera Bio's (ENTX) stock price is being driven by encouraging data from phase II study on EB613, its investigational orally delivered treatment for osteoporosis
RGENNegative Net Change AVIRPositive Net Change ENTXPositive Net Change BNTXNegative Net Change
biotechs
Agenus (AGEN) Soars on Global License Deal With Bristol-Myers
by Zacks Equity Research
Agenus (AGEN) inks a definitive agreement with Bristol-Myers, wherein it will grant license to its bispecific antibody program AGEN1777 and another undisclosed target, to the latter.
BMYNegative Net Change AGENPositive Net Change ADPTPositive Net Change ATNXPositive Net Change
biotechs
Sarepta (SRPT) Rises on Robust DMD Gene Therapy Study Data
by Zacks Equity Research
Sarepta's (SRPT) lead gene therapy candidate, SRP-9001, demonstrates robust improvement in expression of micro-dystrophin protein in DMD patients after 12 weeks of treatment.
RHHBYNegative Net Change PFENegative Net Change SRPTPositive Net Change SLDBPositive Net Change
biotechs
Top 5 S&P 500 Stocks at Lucrative Valuation Amid May Turmoil
by Nalak Das
We have narrowed down our search to five S&P 500 stocks that have attained a 52-week high this year but are currently trading at a deep discount. These are: MAR, PHM, WY, GM and ILMN.
MARNegative Net Change ILMNNegative Net Change WYNegative Net Change PHMNegative Net Change GMNegative Net Change
auto-tires-trucks biotechs construction consumer-discretionary
Why Sarepta Therapeutics (SRPT) Stock Soared on Tuesday
by Madeleine Johnson
Shares of Sarepta Therapeutics (SRPT) closed higher after announcing positive data for its Duchenne Muscular Dystrophy (DMD) drug.
SRPTPositive Net Change
biotechs pharmaceuticals
Find 'Strong Buy' Stocks Near Highs Amid Volatility
by Benjamin Rains
Given this backdrop, investors might want to consider buying stocks that have remained near their highs amid the volatility...
BNTXNegative Net Change
biotechs tech-stocks
Regeneron (REGN) Resumes Enrollment in Lymphoma Cohorts
by Zacks Equity Research
Regeneron (REGN) resumes enrollment in two patient cohorts of pipeline candidate, odronextamab, a CD20xCD3 bispecific antibody, after the FDA lifts partial clinical hold.
REGNNegative Net Change SNYNegative Net Change BAYRYNegative Net Change RGENNegative Net Change
biotechs pharmaceuticals
Incyte (INCY) Announces Positive Results From Vitiligo Study
by Zacks Equity Research
Incyte (INCY) announces positive data from phase III studies on ruxolitinib cream for the treatment of vitiligo.
INCYNegative Net Change NVSNegative Net Change RGENNegative Net Change MORPositive Net Change
biotechs pharmaceuticals
4 Biotech Stocks That Have Already Doubled This Year So Far
by Kinjel Shah
Stocks of BioNTech (BNTX), Ocugen (OCGN), Rubius Therapeutics (RUBY) and Entera Bio (ENTX) are up more than 100% this year so far.
RUBYNegative Net Change ENTXPositive Net Change BNTXNegative Net Change OCGNPositive Net Change
biotechs
Bristol Myers (BMY) Announces New Data on Cardiovascular Candidate
by Zacks Equity Research
Bristol Myers (BMY) announces new positive data on mavacamten from a late-stage study at the American College of Cardiology's 70th Annual Scientific Session.
EXELPositive Net Change BMYNegative Net Change RGENNegative Net Change
biotechs
Biogen (BIIB) Eye Disease Drug Misses Primary Goal in Study
by Zacks Equity Research
Biogen's (BIIB) rare, inherited retinal disease candidate, cotoretigene toliparvovec fails to meet the primary endpoint in a phase II/III study.
BIIBNegative Net Change SGMOPositive Net Change DNLINegative Net Change
biotechs
Apellis' (APLS) Blood Disorder Drug Empaveli Gets FDA Nod
by Zacks Equity Research
The FDA approves Apeliis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients.
ALXNPositive Net Change AZNNegative Net Change APLSPositive Net Change BNTXNegative Net Change
biotechs
Biogen (BIIB) Decides to Acquire Phase II Stroke Candidate
by Zacks Equity Research
Biogen's (BIIB) decision to acquire TMS-007 is based on positive data from a phase IIa study, which met its primary safety objective with no incidence of symptomatic intracranial hemorrhage (sICH)
BIIBNegative Net Change SGMOPositive Net Change DNLINegative Net Change
biotechs
4 Biotech Stocks Set to Outpace Q1 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
FBIOPositive Net Change BYSINegative Net Change AVROPositive Net Change XAIRNegative Net Change
biotechs
Chiasma (CHMA) is Overbought: Is A Drop Coming?
by Zacks Equity Research
Chiasma (CHMA) has moved higher as of late, but there could definitely be trouble on the horizon for this company
CHMAPositive Net Change
biotechs medical
GT Biopharma (GTBP) to Report Q1 Earnings: What to Expect?
by Zacks Equity Research
GT Biopharma (GTBP) is expected to provide updates on its pipeline development when it reports first-quarter 2021 result.
FBIOPositive Net Change GTBPPositive Net Change BYSINegative Net Change AVROPositive Net Change
biotechs
Prothena (PRTA) Q1 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Prothena (PRTA) reports a wider loss in the first quarter of 2021. The pipeline remains in focus with the planned initiation of three late-stage studies for birtamimab, prasinezumab and PRX004.
RHHBYNegative Net Change BMYNegative Net Change RGENNegative Net Change PRTANegative Net Change
biotechs earnings
Biotech Stock Roundup: REGN's Q1 Earnings Update, MRNA's Vaccine Data & More
by Zacks Equity Research
The biotech sector was in focus last week with earnings updates from Regeneron (REGN) and Moderna (MRNA) and regulatory updates from Amgen, among others.
BIIBNegative Net Change REGNNegative Net Change MRNANegative Net Change AMGNPositive Net Change NERVPositive Net Change
biotechs pharmaceuticals
Biogen (BIIB) Signs New Gene Therapy Deal for CNS Disorders
by Zacks Equity Research
Biogen (BIIB) and Capsigen set to collaborate to make AAV capsids that have the potential to deliver transformative gene therapies for various CNS and neuromuscular disorders.
BIIBNegative Net Change SGMOPositive Net Change DNLINegative Net Change
biotechs
Is a Surprise Coming for AVROBIO (AVRO) This Earnings Season?
by Zacks Equity Research
AVROBIO (AVRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AVROPositive Net Change
biotechs medical
Novavax's (NVAX) Q1 Loss Widens, Revenues Beat, Shares Down
by Zacks Equity Research
Novavax (NVAX) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Shares fall in after-hours trading.
SNYNegative Net Change GSKNegative Net Change NVAXNegative Net Change TAKNegative Net Change
biotechs earnings